Találati lista | Tudóstér

001-es BibID:	BIBFORM120113
Első szerző:	Naveen, R.
Cím:	Safety and tolerance of vaccines against SARS-CoV-2 infection in systemic lupus erythematosus : results from the COVAD study / Naveen R., Nikiphorou Elena, Joshi Mrudula, Sen Parikshit, Lindblom Julius, Agarwal Vishwesh, Lilleker James B., Tan Ai Lyn, Salim Babur, Ziade Nelly, Velikova Tsvetelina, Gracia-Ramos Abraham Edgar, Kuwana Masataka, Day Jessica, Makol Ashima, Distler Oliver, Chinoy Hector, Traboco Lisa S., Wibowo Suryo Anggoro Kusumo, Tehozol Erick Adrian Zamora, Serrano Jorge Rojas, García-De La Torre Ignacio, COVAD Study Group, Aggarwal Rohit, Gupta Latika, Agarwal Vikas, Parodis Ioannis
Dátum:	2023
ISSN:	1462-0324 1462-0332
Megjegyzések:	Objective: To determine COVID-19 vaccine-related adverse events (AEs) in the seven-day post-vaccination period in patients with SLE vs autoimmune rheumatic diseases (AIRDs), non-rheumatic autoimmune diseases (nrAIDs), and healthy controls (HC). Methods: Data were captured through the COVID-19 Vaccination in Autoimmune Diseases (COVAD) questionnaire (March-December 2021). Multivariable regression models accounted for age, gender, ethnicity, vaccine type and background treatment. Results: Among 9462 complete respondents, 583 (6.2%) were SLE patients (mean age: 40.1 years; 94.5% females; 40.5% Asian; 42.9% Pfizer-recipients). Minor AEs were reported by 83.0% of SLE patients, major by 2.6%, hospitalization by 0.2%. AE and hospitalization frequencies were similar between patients with active and inactive SLE. Rashes were more frequent in SLE patients vs HC (OR; 95% CI: 1.2; 1.0, 1.5), chills less frequent in SLE vs AIRDs (0.6; 0.4, 0.8) and nrAIDs (0.5; 0.3, 0.8), and fatigue less frequent in SLE vs nrAIDs (0.6; 0.4, 0.9). Pfizer-recipients reported higher overall AE (2.2; 1.1, 4.2) and injection site pain (2.9; 1.6, 5.0) frequencies than recipients of other vaccines, Oxford/AstraZeneca-recipients more body ache, fever, chills (OR: 2.5, 3.0), Moderna-recipients more body ache, fever, chills, rashes (OR: 2.6, 4.3). Hospitalization frequencies were similar across vaccine types. AE frequencies were similar across treatment groups, although chills were less frequent in antimalarial users vs non-users (0.5; 0.3, 0.9). Conclusion: While COVID-19 vaccination-related AEs were reported by four-fifths of SLE patients, those were mostly minor and comparable to AEs reported by healthy individuals, providing reassurance regarding COVID-19 vaccination safety in SLE.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk COVID-19 adverse events rheumatology systemic lupus erythematosus vaccine
Megjelenés:	Rheumatology. - 62 : 7 (2023), p. 2453-2463. -
További szerzők:	Nikiphorou, Elena (reumatológus) Joshi, Mrudula Sen, Parikshit Lindblom, Julius Agarwal, Vishwesh Lilleker, James B. Tan, Ai Lyn Salim, Babur Ziade, Nelly Velikova, Tsvetelina Gracia-Ramos, Abraham Edgar Kuwana, Masataka Day, Jessica Makol, Ashima Distler, Oliver Chinoy, Hector Traboco, Lisa S. Wibowo, Suryo Anggoro Kusumo Tehozol, Erick Adrian Zamora Serrano, Jorge Rojas García-De La Torre, Ignacio Aggarwal, Rohit Gupta, Latika Agarwal, Vikas Parodis, Ioannis Nagy-Vincze Melinda (1985-) (orvos) COVAD Study Group
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: